In a decisive move by the Supreme Court on Thursday, access to the abortion medication mifepristone was unanimously maintained, a relief for those concerned about the potential nationwide restrictions on the drug even in states where abortion remains legal. In what is noted as the court's first major abortion-related decision since the landmark reversal of Roe v. Wade, it was ruled that the group of anti-abortion rights doctors and medical associations did not possess the legal right to challenge the Food and Drug Administration's actions regarding the drug. According to CBS News, the case didn't pass muster on grounds of legal standing, sidestepping what could have been a significant limitation on mifepristone's availability.
Justice Brett Kavanaugh penned the court's opinion, underscoring that plaintiffs' desire to restrict access to a particular medication for others does not equate to legal standing to sue. The doctors, who had brought the lawsuit, do not prescribe nor use mifepristone, which the FDA does not mandate them to do or avoid, Kavanaugh wrote, drawing a firm line on the limits of legal standing in such cases. As reported by KTLA, the verdict continues the availability of a drug involved in a significant number of abortions in the United States—more than 6 million uses since its approval in 2000.
President Joe Biden responded to the court's decision, emphasizing that the availability of mifepristone stands unchanged, though acknowledged that the fight for reproductive rights is ongoing in the wake of Roe's overturning. "Today's decision does not change the fact that the fight for reproductive freedom continues. It does not change the fact that the Supreme Court overturned Roe v. Wade two years ago, and women lost a fundamental freedom," Biden stated, as relayed by CBS News. Conversely, the attorney for the doctors, Erin Hawley, expressed disappointment, vowing to persist in advocacy efforts to restore "commonsense safeguards for abortion drugs."
The Supreme Court's ruling not only curtails the current lawsuit but also brings stability to the FDA's drug approval processes, which were under intense scrutiny. Acknowledging the larger implications of this case, Kavanaugh pointed out that had the court found in favor of the doctors and medical groups, it might have thrown open the door for healthcare practitioners to contest any FDA drug approval—a scenario that pharmaceutical companies and former FDA officials warned against. Danco Laboratories, the producer of mifepristone, welcomed the Supreme Court's stance, appreciating the reaffirmation of "longstanding basic principles of administrative law," per a spokesperson's statement summarized by CBS News.
